Clinical trials company Hvivo has completed its first acquisition, buying two research units from German group CRS for €10 ...

LONDON - hVIVO plc, a leading early-stage Contract Research Organisation (CRO) known for its human challenge clinical trials, has acquired two Clinical Research Units (CRUs) from CRS Clinical Research ...

Condition affects about 16m people per year, and accounts for about 160,700 deaths in children younger than five ...

Hvivo paid £10 million in cash for the takeover of CRS, a German clinical trial firm with two research units, marking the ...

ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis ...

VIVO, a fast-growing early-stage German contract research organization (CRO) has acquired two clinical research units from Clinical Research Services (CRS), in Mannheim and Kiel, Germany, for a total ...

For investors searching for shares to buy in February, this small UK firm might be worth considering for inclusion in a ...

(Alliance News) - hVIVO PLC on Wednesday released an optimistic pre-annual results trading update, and said it expects "further strong growth" next year. However, the stock was down 7.4% at 18.89 ...

VIVO announced on Tuesday that it has secured its largest standalone laboratory contract to date, with its hLAB division ...

(Sharecast News) - hVIVO announced on Monday that it has signed a letter of intent with ILiAD Biotechnologies to conduct a pivotal phase three human challenge trial for ILiAD's lead whooping cough ...

hVIVO is a specialist contract research organization (CRO) and a world leader in human challenge models. A human challenge trial overcomes the complexities associated with conducting traditional ...